About: CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.87 (+6.61%)
GDTC NASDAQ CytoMed Therapeutics Limited Ordinary Shares
CytoMed Therapeutics Limited Ordinary Shares share price
GDTC price activity
Last Price
$0.870
Change (24hr)
0.05 USD (6.61%)
Volume
23.86K
Volume (4w avg)
-
Open
$0.83
Day Range
$0.82 - $0.87
Previous Close
$0.81
Last Trade
13 Oct, 7:59 pm GMT+0
Delayed
13 Oct, 7:59 pm GMT+0
GDTC price performance
Delayed
13 Oct, 7:59 pm GMT+0
GDTC Market Signals